S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
A One Stop Shop for Everything Futures Trading (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
A One Stop Shop for Everything Futures Trading (Ad)pixel
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
A One Stop Shop for Everything Futures Trading (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
A One Stop Shop for Everything Futures Trading (Ad)pixel
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
A One Stop Shop for Everything Futures Trading (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
A One Stop Shop for Everything Futures Trading (Ad)pixel
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
A One Stop Shop for Everything Futures Trading (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
A One Stop Shop for Everything Futures Trading (Ad)pixel
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
NYSE:BIO

Bio-Rad Laboratories - BIO Stock Forecast, Price & News

$417.14
-1.10 (-0.26%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$416.86
$427.48
50-Day Range
$412.59
$563.26
52-Week Range
$406.24
$798.97
Volume
263,414 shs
Average Volume
156,900 shs
Market Capitalization
$12.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$705.00

Bio-Rad Laboratories MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
69.0% Upside
$705.00 Price Target
Short Interest
Healthy
1.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.66mentions of Bio-Rad Laboratories in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$278,166 Sold Last Quarter
Proj. Earnings Growth
9.06%
From $14.35 to $15.65 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.82 out of 5 stars

Medical Sector

70th out of 1,093 stocks

Analytical Instruments Industry

6th out of 29 stocks

BIO stock logo

About Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

10 Stocks Billionaire Ken Fisher May Never Sell
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Company Calendar

Last Earnings
7/28/2022
Today
10/01/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
09057220
Employees
7,900
Year Founded
1952

Price Target and Rating

Average Stock Price Forecast
$705.00
High Stock Price Forecast
$715.00
Low Stock Price Forecast
$700.00
Forecasted Upside/Downside
+69.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$4.25 billion
Pretax Margin
-90.90%

Debt

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$15.76 per share
Book Value
$456.60 per share

Miscellaneous

Free Float
21,561,000
Market Cap
$12.39 billion
Optionable
Optionable
Beta
0.99

Social Links


Key Executives

  • Norman D. Schwartz
    Chairman, President & Chief Executive Officer
  • Andrew J. Last
    Chief Operating Officer & Executive Vice President
  • Ilan DaskalIlan Daskal
    Chief Financial Officer & Executive Vice President
  • Simon May
    Executive VP & President-Life Science Group
  • Timothy S. ErnstTimothy S. Ernst
    Secretary, Executive VP & General Counsel













BIO Stock - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIO shares.
View BIO analyst ratings
or view top-rated stocks.

What is Bio-Rad Laboratories' stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Bio-Rad Laboratories' shares. Their BIO share price forecasts range from $700.00 to $715.00. On average, they predict the company's stock price to reach $705.00 in the next year. This suggests a possible upside of 69.0% from the stock's current price.
View analysts price targets for BIO
or view top-rated stocks among Wall Street analysts.

How have BIO shares performed in 2022?

Bio-Rad Laboratories' stock was trading at $755.57 at the start of the year. Since then, BIO stock has decreased by 44.8% and is now trading at $417.14.
View the best growth stocks for 2022 here
.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 367,600 shares, an increase of 24.0% from the August 15th total of 296,500 shares. Based on an average trading volume of 146,100 shares, the short-interest ratio is currently 2.5 days. Approximately 1.7% of the shares of the company are sold short.
View Bio-Rad Laboratories' Short Interest
.

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our BIO earnings forecast
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its earnings results on Thursday, July, 28th. The medical research company reported $3.38 EPS for the quarter, topping the consensus estimate of $2.46 by $0.92. The medical research company earned $691.10 million during the quarter, compared to the consensus estimate of $664.60 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 3.82% and a negative net margin of 67.66%. The business's revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.54 earnings per share.
Read the conference call transcript
.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.95 billion-$2.95 billion, compared to the consensus revenue estimate of $2.85 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $417.14.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $12.39 billion and generates $2.92 billion in revenue each year. The medical research company earns $4.25 billion in net income (profit) each year or ($66.32) on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

The company employs 7,900 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?
The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.

This page (NYSE:BIO) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.